CD8A and neoplasm: Furthermore, SUV39H2 inhibition significantly enhances oHSV-1 replication within tumor tissues and promotes CD4+ T and CD8+ T immune cell infiltration into the tumor microenvironment, ultimately improving the virus’s oncolytic efficacy.